查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030181

失智症和阿茲海默症治療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類別、分銷管道、地區和競爭格局分類，2021-2031年

Dementia and Alzheimer's Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球失智症和阿茲海默症治療市場預計將從 2025 年的 121.8 億美元成長到 2031 年的 179.1 億美元，複合年成長率為 6.64%。

該領域涵蓋旨在控制與阿茲海默症神經退化性疾病相關的行為障礙和認知衰退的藥物和非藥物治療方法。這一領域的成長主要得益於全球範圍內因老化導致的失智症發病率上升、公眾意識的提高促成了更早期的診斷，以及用於闡明疾病機制和尋找新治療靶點的研究的大量資金投入。 2025年10月，世界失智症會引用世界衛生組織（世衛組織）的數據估計，截至2023年，全球約有5,500萬人患有失智症。

市場概覽
預測期 2027-2031
市場規模：2025年 121.8億美元
市場規模：2031年 179.1億美元
複合年成長率：2026-2031年 6.64%
成長最快的細分市場 膽鹼能促效劑/膽鹼酯酶（ChE）抑制劑
最大的市場 北美洲

市場發展也得益於診斷工具的改善和全球醫療保健體系的擴張。然而，這項擴張的主要障礙包括研發新治療方法和獲得監管部門核准所需的高昂成本和漫長時間，以及現有治療方法在真正改變疾病進程方面效果有限。

市場促進因素

緩解疾病療法的進步正對全球阿茲海默症和失智症治療市場產生重大影響，治療方法能夠針對疾病的根本原因進行治療，而不僅僅是緩解症狀。能夠延緩疾病進展或清除有害蛋白的創新藥物的出現，正在改變治療方法，並為患者及其家人帶來新的希望。新核准藥物的商業性化應用日益廣泛，清楚地體現了這一轉變。根據渤健公司於2026年2月發布的2025年第四季財報，Lekenbi（lecanemab）的全球銷售額約為1.34億美元。這反映出市場對標靶機制治療方法的明確需求，進而推動了該領域的進一步投資和創新，拓展了治療選擇，並促進了早期診斷工作，以找到合適的候選患者。

除了這些臨床突破之外，研發經費的增加也是市場擴張的主要動力。來自公私機構的資金支持不斷擴大，為阿茲海默症和失智症治療方法提供了支持。這些資金透過支持多種研究策略，包括對新生物標記、遺傳因素和特定疾病路徑的研究，加速了研發進程。 2025年7月，阿茲海默症協會在其報告《參議院核准委員會核准增加1億美元阿茲海默症研究經費》中強調，參議院核准委員會已核准為美國國立衛生研究院（NIH）2026會計年度的失智症和阿茲海默症研究增加1億美元的經費。鑑於這些疾病帶來的巨大經濟影響，這種持續的資金支持至關重要。阿茲海默症協會估計，到 2025 年，美國失智症患者的醫療保健和長期照護費用將達到 3,840 億美元，這凸顯了為應對這種棘手疾病提供解決方案的資金至關重要。

市場挑戰

開發新治療方法並獲得監管部門核准需要耗資巨資和漫長的時間，這嚴重阻礙了失智症和阿茲海默症療法在全球範圍內的推廣。從藥物發現到各種臨床試驗階段，直到最終獲得市場核准，都需要巨額資金，而每個階段的耗時又很長，這構成了製藥研發人員面臨的主要障礙。

神經退化性疾病治療藥物研發中極高的失敗率進一步加劇了這一障礙，因為許多前景看好的治療方法在後期臨床試驗中未能展現出足夠的安全性和有效性。這些挫折導致資金浪費，並延誤了急需有效治療方法的患者獲得治療的時間。 2024年，生技創新組織（BIO）指出，所有疾病領域新療法候選藥物的臨床開發成功率僅6.7%。如此低的監管核准成功率阻礙了對中樞神經系統療法的資金投入，從而限制了市場成長所需的突破性治療方法的供應。

市場趨勢

個人化醫療策略的重大轉變正在重塑全球阿茲海默症和失智症治療市場。這種方法旨在摒棄「一刀切」的治療模式，根據患者獨特的遺傳背景、生物標記指標和疾病進展來客製化治療方案。個人化治療至關重要，因為阿茲海默症是一種複雜的疾病，個體對不同藥物的反應也各不相同。這項轉變得到了大量專項研究經費的支持。 2026年1月8日，阿茲海默症協會發表聲明，題為“阿茲海默症協會撥款1100萬美元用於‘撥開迷霧’創新治療方法津貼”，宣布其項目已撥款超過1100萬美元用於資助突破性治療方法。這表明個人化醫療是阿茲海默症治療的下一個前沿領域。這些努力旨在識別最能從標靶治療中獲益的特定病患小組，最終提高治療成功率，並確保在臨床試驗和日常醫療實踐中更有效地利用資源。

另一個重要趨勢是利用生物標記進行早期檢測的持續進展。這對於快速啟動治療至關重要，尤其是在認知障礙早期階段，緩解疾病藥物最為有效。該領域的突破性進展，特別是基於血液的生物標記物，使得檢測更加便捷，同時降低了腦脊髓液檢測和PET掃描等傳統方法的成本和不適感。這項進展得到了旨在開發先進診斷設備的大規模資金支持。 2026年3月17日，阿茲海默症基金會（ADDF）在一份題為「ADDF啟動1.5億美元診斷加速器計畫新階段，以推進舉措阿茲海默症下一代精準醫療」的聲明中宣布，將向其診斷加速器計畫追加5,000萬美元投資。這將使該計畫的總資金達到1.5億美元，加速推進這些關鍵生物標記技術的研發。診斷技術的進步將有助於更早識別患者。這是最佳化新治療方法的有效性以及對臨床研究參與者進行適當分類的關鍵步驟。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：失智症和阿茲海默症治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（膽鹼能促效劑/膽鹼酯酶（ChE）抑制劑、Memantine、組合藥物、其他）
    • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美失智症和阿茲海默症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲失智症和阿茲海默症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區失智症和阿茲海默症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲失智症和阿茲海默症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲失智症和阿茲海默症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球失智症和阿茲海默症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • H. Lundbeck A/S
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Corium, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5058

The Global market for dementia and Alzheimer's disease treatments is anticipated to expand from USD 12.18 billion in 2025 to USD 17.91 billion by 2031, reflecting a compound annual growth rate of 6.64%. This sector includes both medical and non-medical therapies designed to manage the behavioral issues and cognitive deterioration linked to neurodegenerative disorders like Alzheimer's. Growth is largely fueled by the rising global incidence of dementia linked to an aging demographic, increased awareness resulting in prompt diagnoses, and substantial financial backing for research aimed at uncovering disease mechanisms and new treatment targets. In October 2025, the World Medical Association referenced the World Health Organization, noting that approximately 55 million people worldwide were living with dementia in 2023.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 12.18 Billion
Market Size 2031USD 17.91 Billion
CAGR 2026-20316.64%
Fastest Growing SegmentCholinergic/ Cholinesterase (ChE) Inhibitors
Largest MarketNorth America

Market progress is additionally supported by improved diagnostic tools and growing healthcare systems worldwide. Nevertheless, a major obstacle to this expansion is the high expense and extended time required to develop and secure regulatory clearance for novel therapies, coupled with the limited success of current treatments in truly changing the course of the disease.

Market Driver

Progress in disease-modifying treatments is profoundly influencing the worldwide market for Alzheimer's and dementia care by delivering therapies that target the root causes of the condition instead of just alleviating symptoms. The rollout of innovative drugs that can slow the disease's advancement or clear harmful proteins is changing how these conditions are treated, bringing renewed optimism to affected individuals and their loved ones. The rising commercial adoption of newly authorized medications highlights this shift; Biogen's Q4 2025 financial results from February 2026 revealed that global sales for Leqembi (lecanemab) reached roughly $134 million. This reflects a clear market demand for mechanism-targeting treatments, which in turn spurs further investment and innovation in the field, broadening treatment options and motivating earlier diagnostic initiatives to find suitable candidates.

Alongside these clinical breakthroughs, increased funding for research and development acts as a major driver for market expansion. Boosted financial support from private and public entities powers the complex and expensive journey of drug discovery, laboratory testing, and clinical evaluations for novel Alzheimer's and dementia therapies. Such funding speeds up the development process by backing various investigative strategies, such as studying new biomarkers, genetic factors, and distinct disease pathways. In July 2025, the Alzheimer's Association highlighted in the report 'Senate Appropriations Committee Approves $100 Million Increase for Alzheimer's Research' that the Senate Appropriations Committee authorized a $100 million boost in research funding for dementia and Alzheimer's at the National Institutes of Health for fiscal year 2026. This ongoing financial dedication is essential due to the massive economic impact of these illnesses; the Alzheimer's Association estimated that U.S. health and long-term care expenses for those with dementia would hit $384 billion in 2025, underscoring the critical need to fund solutions for this challenging condition.

Market Challenge

The substantial expenses and extended periods needed to create and secure regulatory clearance for new therapies severely hinder the expansion of the worldwide dementia and Alzheimer's disease treatment sector. The massive capital required to advance a medication from initial discovery across various clinical trial stages to final market approval, combined with the lengthy timeframes required for each phase, establishes a massive hurdle for pharmaceutical developers.

This obstacle is worsened by the exceptionally high failure rates seen in the development of drugs for neurodegenerative conditions, as many prospective treatments do not show adequate safety or effectiveness during advanced clinical trials. These setbacks result in wasted financial resources and extend the delay for patients desperate for helpful interventions. In 2024, the Biotechnology Innovation Organization (BIO) noted that the success rate for new therapeutic candidates navigating clinical development was merely 6.7 percent across all medical conditions. Such poor odds of regulatory success discourage financial backing for central nervous system treatments, ultimately limiting the flow of groundbreaking therapies required for the market to grow.

Market Trends

A major movement reshaping the worldwide market for Alzheimer's and dementia therapies is the increasing transition toward customized medical strategies. This approach seeks to customize care using a patient's distinct genetic background, biomarker indicators, and disease trajectory, departing from universal treatment models. Personalized methods are vital because Alzheimer's is a complex disease, causing individuals to react differently to various medications. This shift is supported by heavy funding in specialized studies; on January 8, 2026, the Alzheimer's Association announced in 'Alzheimer's Association Part the Cloud Grants $11 Million to Develop Innovative Treatments' that its program awarded over $11 million to fund groundbreaking therapies, acknowledging personalized medicine as the next frontier in Alzheimer's care. Such initiatives aim to pinpoint specific patient groups that will gain the most from targeted treatments, ultimately boosting success rates and ensuring better use of resources in both research trials and everyday medical settings.

An additional key trend is the ongoing progress in early detection using biomarkers, which is essential for initiating prompt treatment, especially since disease-modifying drugs work best during the initial phases of cognitive impairment. Breakthroughs in this field, notably involving blood-based biomarkers, are making testing more accessible while lowering the expenses and discomfort linked to conventional procedures like cerebrospinal fluid tests and PET scans. This momentum is supported by major financial commitments designed to create advanced diagnostic instruments; on March 17, 2026, the Alzheimer's Drug Discovery Foundation (ADDF) revealed in 'ADDF Launches New Phase of $150 Million Diagnostics Accelerator Initiative to Power Next Generation of Alzheimer's Precision Medicine Worldwide' an extra $50 million for its Diagnostics Accelerator, increasing the program's total funding to $150 million to push forward these vital biomarker technologies. These improvements in diagnostics allow for the faster identification of patients, a crucial step for optimizing the effectiveness of new therapies and properly categorizing participants for clinical research.

Key Market Players

  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • H. Lundbeck A/S
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Corium, Inc.

Report Scope

In this report, the Global Dementia and Alzheimer's Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dementia and Alzheimer's Disease Treatment Market, By Drug Class

  • Cholinergic/ Cholinesterase (ChE) Inhibitors
  • Memantine
  • Combination Drugs
  • Others

Dementia and Alzheimer's Disease Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Dementia and Alzheimer's Disease Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dementia and Alzheimer's Disease Treatment Market.

Available Customizations:

Global Dementia and Alzheimer's Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dementia and Alzheimer's Disease Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, Combination Drugs, Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Dementia and Alzheimer's Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dementia and Alzheimer's Disease Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Dementia and Alzheimer's Disease Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Dementia and Alzheimer's Disease Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel

7. Europe Dementia and Alzheimer's Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Dementia and Alzheimer's Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Dementia and Alzheimer's Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Dementia and Alzheimer's Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Dementia and Alzheimer's Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Dementia and Alzheimer's Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. South America Dementia and Alzheimer's Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dementia and Alzheimer's Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Dementia and Alzheimer's Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Dementia and Alzheimer's Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Dementia and Alzheimer's Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merz Pharma GmbH & Co. KGaA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Pfizer, Inc.
  • 15.4. Ono Pharmaceutical Co., Ltd.
  • 15.5. Johnson & Johnson Services, Inc.
  • 15.6. H. Lundbeck A/S
  • 15.7. F. Hoffmann-La Roche Ltd.
  • 15.8. AbbVie Inc.
  • 15.9. Eli Lilly and Company
  • 15.10. Corium, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer